A Phase 3 interventional study of Alirocumab and Lipid-Modifying Therapy (LMT) in Hypercholesterolemia, sponsored by Sanofi. Completed at 177 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-07-24.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.
Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 5th largest by enrollment, is one of 6 that started in 2013, is one of 20 in phase 3, and was the 24th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18+
By country, each count listing its studies:
alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 6 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 986 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 107 across the 43 interventional studies. Of the 40 that completed or were terminated, 30 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 43 have an industry lead sponsor. The 6 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
38 studies in Hypercholesterolemia by Sanofi: none open now, none under way, none of them phase 3. Of 38 finished, 22 (58%) have results posted.
Among the 38 studies in Hypercholesterolemia by Sanofi, this one is the 5th largest by enrollment, is one of 5 that started in 2013, is one of 22 in phase 3, and was the 23rd registered.
Sanofi’s Hypercholesterolemia studies by the year they started, since 2007.
2 of the studies testing alirocumab in Hypercholesterolemia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07477704Regeneron PharmaceuticalsA Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia | 2026-12-29 |
| NCT07581808University Medical Centre LjubljanaDual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 43 studies testing alirocumab in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 38 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To assess the long-term safety of alirocumab (SAR236553/REGN727) when added to lipid-lowering therapy in participants with heterozygous familial hypercholesterolemia (heFH) who had completed EFC12492 (NCT01623115), R727-CL-1112 (NCT01709500), EFC12732 (NCT01617655) and LTS11717 (NCT01507831).
Secondary Objectives:
The maximum study duration will be 176 weeks per participant.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants with heFH who had completed one of the four parent studies (EFC12492, R727-CL-1112, EFC12732 and LTS11717).
Exclusion criteria:
Significant protocol deviation in the parent study; Any permanent treatment discontinuation from the parent study.
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Alirocumab 75 mg or 150 mg every 2 weeks (Q2W) added to stable lipid-modifying therapy (LMT) for up to 168 additional weeks (or until the product was commercially available) in participants who completed the parent studies EFC12492, R727-CL-1112, EFC12732 and LTS11717.
Drug: Alirocumab · Drug: Lipid-Modifying Therapy (LMT)
Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a pre-filled syringe.
Also known as: SAR236553, REGN727, Praluent
Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
Percentage of Participants Who Experienced Adverse Events (AEs)
Reported AEs are treatment-emergent AEs that is AEs that developed/worsened during the 'treatment-emergent period' (the time from the first dose of alirocumab in this study up to the last dose of alirocumab received in this study +70 days). Clinically significant lab and vital sign abnormalities were to be reported as AEs.
Time frame: Up to 10 weeks after last study drug administration (maximum of 176 weeks)
Percent Change From Baseline in Calculated LDL-C at Weeks 8, 24, 48, 72, 96, 120, 144 and 168
Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.
Time frame: Parent Baseline, Weeks 8, 24, 48, 72, 96, 120, 144, and 168
Absolute Change From Baseline in Calculated LDL-C (mg/dL) at Weeks 8, 24, 48, 72, 96, 120, 144 and 168
Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.
Time frame: Parent Baseline, Weeks 8, 24, 48, 72, 96, 120, 144, and 168
Absolute Change From Baseline in Calculated LDL-C (mmol/L) at Weeks 8, 24, 48, 72, 96, 120, 144 and 168
Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.
Time frame: Parent Baseline, Weeks 8, 24, 48, 72, 96, 120, 144, and 168
Percentage of Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) Over Time
Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.
Time frame: Parent Baseline, Weeks 8, 24, 48, 72, 96, 120, 144, and 168
Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) Over Time
Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.
Time frame: Parent Baseline, Weeks 8, 24, 48, 72, 96, 120, 144, and 168
Percentage of Participants With Calculated LDL-C <70 mg/dL (1.81mmol/L) and/or >=50% Reduction in Calculated LDL-C From Baseline (if Calculated LDL-C >=70 mg/dL [1.81mmol/L]) Over Time
Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.
Time frame: Parent Baseline, Weeks 8, 24, 48, 72, 96, 120, 144, and 168
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Weeks 8, 24, 48, 72, 96, 120, 144 and 168
Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.
Time frame: Parent Baseline, Weeks 8, 24, 48, 72, 96, 120, 144, and 168
Percent Change From Baseline in Total-cholesterol at Weeks 8, 24, 48, 72, 96, 120, 144 and 168
Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.
Time frame: Parent Baseline, Weeks 8, 24, 48, 72, 96, 120, 144, and 168
Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Weeks 8, 24, 48, 72, 96, 120, 144 and 168
Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.
Time frame: Parent Baseline, Weeks 8, 24, 48, 72, 96, 120, 144, and 168
Percent Change From Baseline in Fasting Triglycerides (TGs) at Weeks 8, 24, 48, 72, 96, 120, 144 and 168
Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.
Time frame: Parent Baseline, Weeks 8, 24, 48, 72, 96, 120, 144, and 168
Percent Change From Baseline in Lipoprotein (a) at Weeks 48, 96, 144 and 168
Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.
Time frame: Parent Baseline, Weeks 48, 96, 144, and 168
Percent Change From Baseline in Apolipoprotein-B (Apo-B) at Weeks 48, 96, 144, and 168
Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.
Time frame: Parent Baseline, Weeks 48, 96, 144, and 168
Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Weeks 48, 96, 144, and 168
Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.
Time frame: Parent Baseline, Weeks 48, 96, 144, and 168
Absolute Change From Baseline in Apo B/Apo A-1 Ratio at Weeks 48, 96, 144, and 168
Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.
Time frame: Parent Baseline, Weeks 48, 96, 144, and 168
The study was conducted at 177 centers in 24 countries. Overall, 986 participants who completed study EFC12492 (NCT01623115), R727-CL-1112 (NCT01709500), EFC12732 (NCT01617655) and LTS11717 (NCT01507831) were enrolled between December 2013 and December 2014.
| Milestone | Placebo to Alirocumab 75 or 150 mg Q2W | Alirocumab to Alirocumab 75 or 150 mg Q2W |
|---|---|---|
| Started | 331 | 655 |
| Treated | 330 | 655 |
| Completed | 301 | 598 |
| Not completed | 30 | 57 |
| Withdrew: Enrolled but not treated | 1 | 0 |
| Withdrew: Adverse event | 10 | 23 |
| Withdrew: Poor compliance to protocol | 7 | 7 |
| Withdrew: Participant moved | 0 | 4 |
| Withdrew: Related to study drug administration | 2 | 2 |
| Withdrew: Other than specified above | 10 | 21 |
Reported AEs are treatment-emergent AEs that is AEs that developed/worsened during the 'treatment-emergent period' (the time from the first dose of alirocumab in this study up to the last dose of alirocumab received in this study +70 days). Clinically significant lab and vital sign abnormalities were to be reported as AEs.
| percentage of participants | Placebo to Alirocumab 75 or 150 mg Q2W | Alirocumab to Alirocumab 75 or 150 mg Q2W | Alirocumab: All Participants |
|---|---|---|---|
| Any AE | 83.9 | 87.3 | 86.2 |
| Any Serious AE | 20.6 | 22.0 | 21.5 |
| Any AE leading to treatment discontinuation | 3.0 | 3.5 | 3.4 |
Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.
| percent change | Placebo to Alirocumab 75 or 150 mg Q2W | Alirocumab to Alirocumab 75 or 150 mg Q2W | Alirocumab: All Participants |
|---|---|---|---|
| Week 8 | -44.9 ± 25.9 | -43.8 ± 28.7 | -44.2 ± 27.8 |
| Week 24 | -46.9 ± 27.5 | -46.9 ± 29.3 | -46.9 ± 28.7 |
| Week 48 | -45.6 ± 28.0 | -47.5 ± 28.8 | -46.9 ± 28.6 |
| Week 72 | -47.7 ± 23.5 | -47.3 ± 28.4 | -47.4 ± 26.8 |
| Week 96 | -47.4 ± 23.8 | -48.2 ± 28.2 | -47.9 ± 26.8 |
| Week 120 | -47.4 ± 24.0 | -46.6 ± 31.1 | -46.8 ± 28.8 |
| Week 144 | -46.5 ± 25.8 | -49.6 ± 24.6 | -48.5 ± 25.0 |
| Week 168 | -43.6 ± 13.4 | -52.2 ± 20.7 | -48.8 ± 17.8 |
Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.
| mg/dL | Placebo to Alirocumab 75 or 150 mg Q2W | Alirocumab to Alirocumab 75 or 150 mg Q2W | Alirocumab: All Participants |
|---|---|---|---|
| Week 8 | -66.8 ± 45.6 | -67.1 ± 49.2 | -67.0 ± 48.0 |
| Week 24 | -70.3 ± 49.5 | -72.7 ± 52.4 | -71.9 ± 51.4 |
| Week 48 | -67.8 ± 49.7 | -73.9 ± 54.3 | -71.9 ± 52.8 |
| Week 72 | -71.2 ± 44.5 | -74.9 ± 54.5 | -73.7 ± 51.4 |
| Week 96 | -70.2 ± 45.9 | -75.9 ± 55.0 | -74.0 ± 52.2 |
| Week 120 | -72.3 ± 45.6 | -75.2 ± 59.7 | -74.2 ± 55.2 |
| Week 144 | -73.1 ± 50.0 | -86.2 ± 57.8 | -81.6 ± 55.4 |
| Week 168 | -66.1 ± 24.7 | -99.4 ± 48.3 | -86.1 ± 42.4 |
Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.
| mmol/L | Placebo to Alirocumab 75 or 150 mg Q2W | Alirocumab to Alirocumab 75 or 150 mg Q2W | Alirocumab: All Participants |
|---|---|---|---|
| Week 8 | -1.729 ± 1.180 | -1.738 ± 1.273 | -1.735 ± 1.242 |
| Week 24 | -1.821 ± 1.282 | -1.883 ± 1.356 | -1.863 ± 1.332 |
| Week 48 | -1.757 ± 1.286 | -1.914 ± 1.405 | -1.861 ± 1.368 |
| Week 72 | -1.843 ± 1.154 | -1.940 ± 1.411 | -1.908 ± 1.332 |
| Week 96 | -1.818 ± 1.190 | -1.965 ± 1.426 | -1.916 ± 1.353 |
| Week 120 | -1.874 ± 1.180 | -1.949 ± 1.546 | -1.923 ± 1.428 |
| Week 144 | -1.894 ± 1.294 | -2.232 ± 1.498 | -2.114 ± 1.436 |
| Week 168 | -1.712 ± 0.641 | -2.574 ± 1.252 | -2.229 ± 1.098 |
Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.
| percentage of participants | Placebo to Alirocumab 75 or 150 mg Q2W | Alirocumab to Alirocumab 75 or 150 mg Q2W | Alirocumab: All Participants |
|---|---|---|---|
| Baseline | 12.1 | 11.5 | 11.7 |
| Week 8 | 71.0 | 86.1 | 81.1 |
| Week 24 | 77.0 | 75.7 | 76.1 |
| Week 48 | 77.7 | 76.4 | 76.8 |
| Week 72 | 82.9 | 77.6 | 79.4 |
| Week 96 | 79.2 | 76.8 | 77.6 |
| Week 120 | 78.2 | 76.7 | 77.2 |
| Week 144 | 72.5 | 74.4 | 73.7 |
| Week 168 | 75.0 | 83.3 | 80.0 |
Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.
| percentage of participants | Placebo to Alirocumab 75 or 150 mg Q2W | Alirocumab to Alirocumab 75 or 150 mg Q2W | Alirocumab: All Participants |
|---|---|---|---|
| Baseline | 0.9 | 1.2 | 1.1 |
| Week 8 | 47.4 | 66.4 | 60.1 |
| Week 24 | 53.4 | 53.1 | 53.2 |
| Week 48 | 51.1 | 53.5 | 52.7 |
| Week 72 | 57.0 | 53.2 | 54.5 |
| Week 96 | 53.0 | 56.4 | 55.3 |
| Week 120 | 52.7 | 50.9 | 51.5 |
| Week 144 | 46.4 | 48.1 | 47.5 |
| Week 168 | 50.0 | 33.3 | 40.0 |
Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.
| percentage of participants | Placebo to Alirocumab 75 or 150 mg Q2W | Alirocumab to Alirocumab 75 or 150 mg Q2W | Alirocumab: All Participants |
|---|---|---|---|
| Baseline | 0.9 | 1.2 | 1.1 |
| Week 8 | 49.5 | 67.1 | 61.3 |
| Week 24 | 54.1 | 54.3 | 54.2 |
| Week 48 | 52.1 | 54.5 | 53.7 |
| Week 72 | 57.3 | 54.4 | 55.4 |
| Week 96 | 53.0 | 57.7 | 56.1 |
| Week 120 | 53.2 | 53.1 | 53.1 |
| Week 144 | 46.4 | 48.8 | 48.0 |
| Week 168 | 50.0 | 33.3 | 40.0 |
Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.
| percent change | Placebo to Alirocumab 75 or 150 mg Q2W | Alirocumab to Alirocumab 75 or 150 mg Q2W | Alirocumab: All Participants |
|---|---|---|---|
| Week 8 | -38.1 ± 24.8 | -37.6 ± 26.6 | -37.8 ± 26.0 |
| Week 24 | -40.6 ± 25.5 | -40.4 ± 27.9 | -40.5 ± 27.1 |
| Week 48 | -39.7 ± 25.5 | -40.6 ± 27.6 | -40.3 ± 26.9 |
| Week 72 | -40.8 ± 22.6 | -40.3 ± 26.5 | -40.5 ± 25.3 |
| Week 96 | -39.9 ± 23.5 | -40.5 ± 26.6 | -40.3 ± 25.6 |
| Week 120 | -41.4 ± 22.1 | -38.4 ± 29.7 | -39.5 ± 27.3 |
| Week 144 | -39.8 ± 22.9 | -41.8 ± 24.0 | -41.1 ± 23.6 |
| Week 168 | -40.7 ± 12.3 | -47.7 ± 18.8 | -44.9 ± 16.1 |
Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.
| percent change | Placebo to Alirocumab 75 or 150 mg Q2W | Alirocumab to Alirocumab 75 or 150 mg Q2W | Alirocumab: All Participants |
|---|---|---|---|
| Week 8 | -27.9 ± 19.3 | -27.7 ± 20.7 | -27.7 ± 20.2 |
| Week 24 | -30.1 ± 20.3 | -30.2 ± 21.6 | -30.1 ± 21.2 |
| Week 48 | -29.0 ± 20.5 | -30.0 ± 21.6 | -29.7 ± 21.2 |
| Week 72 | -29.9 ± 18.0 | -30.1 ± 20.8 | -30.0 ± 19.9 |
| Week 96 | -28.9 ± 18.3 | -29.9 ± 21.1 | -29.6 ± 20.2 |
| Week 120 | -30.2 ± 17.2 | -28.4 ± 22.8 | -29.0 ± 21.0 |
| Week 144 | -29.1 ± 18.2 | -31.3 ± 19.1 | -30.5 ± 18.8 |
| Week 168 | -32.3 ± 12.4 | -39.1 ± 14.3 | -36.4 ± 13.3 |
Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.
| percent change | Placebo to Alirocumab 75 or 150 mg Q2W | Alirocumab to Alirocumab 75 or 150 mg Q2W | Alirocumab: All Participants |
|---|---|---|---|
| Week 8 | 5.6 ± 17.1 | 6.6 ± 17.3 | 6.3 ± 17.3 |
| Week 24 | 5.7 ± 17.4 | 5.8 ± 16.9 | 5.8 ± 17.1 |
| Week 48 | 7.1 ± 17.8 | 7.2 ± 19.2 | 7.2 ± 18.7 |
| Week 72 | 6.7 ± 17.6 | 7.2 ± 19.9 | 7.0 ± 19.1 |
| Week 96 | 7.2 ± 18.8 | 7.2 ± 18.7 | 7.2 ± 18.7 |
| Week 120 | 8.0 ± 18.4 | 8.1 ± 18.7 | 8.1 ± 18.6 |
| Week 144 | 8.8 ± 19.2 | 8.8 ± 24.8 | 8.8 ± 23.0 |
| Week 168 | -6.6 ± 26.2 | -0.3 ± 9.9 | -2.8 ± 17.1 |
Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.
| percent change | Placebo to Alirocumab 75 or 150 mg Q2W | Alirocumab to Alirocumab 75 or 150 mg Q2W | Alirocumab: All Participants |
|---|---|---|---|
| Week 8 | 3.4 ± 40.5 | 3.5 ± 47.0 | 3.5 ± 44.9 |
| Week 24 | 0.6 ± 39.9 | 1.0 ± 45.9 | 0.9 ± 44.0 |
| Week 48 | 0.8 ± 37.5 | 5.1 ± 78.0 | 3.7 ± 67.2 |
| Week 72 | 4.3 ± 43.3 | 3.6 ± 42.9 | 3.8 ± 43.0 |
| Week 96 | 9.1 ± 53.2 | 9.3 ± 55.2 | 9.2 ± 54.5 |
| Week 120 | -1.2 ± 35.3 | 10.8 ± 48.5 | 6.7 ± 44.8 |
| Week 144 | 5.0 ± 38.0 | 7.7 ± 49.8 | 6.8 ± 45.9 |
| Week 168 | -22.1 ± 21.9 | -10.3 ± 27.1 | -15.0 ± 24.6 |
Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.
| percent change | Placebo to Alirocumab 75 or 150 mg Q2W | Alirocumab to Alirocumab 75 or 150 mg Q2W | Alirocumab: All Participants |
|---|---|---|---|
| Week 48 | -15.0 ± 158.4 | -26.4 ± 40.2 | -22.6 ± 97.6 |
| Week 96 | -13.9 ± 171.7 | -21.4 ± 132.7 | -18.9 ± 146.9 |
| Week 144 | -20.1 ± 46.1 | -33.0 ± 25.0 | -28.5 ± 34.3 |
| Week 168 | -30.3 ± 18.2 | -29.2 ± 15.4 | -29.6 ± 15.6 |
Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.
| percent change | Placebo to Alirocumab 75 or 150 mg Q2W | Alirocumab to Alirocumab 75 or 150 mg Q2W | Alirocumab: All Participants |
|---|---|---|---|
| Week 48 | -36.9 ± 21.7 | -37.8 ± 23.4 | -37.5 ± 22.9 |
| Week 96 | -36.9 ± 20.9 | -38.0 ± 22.9 | -37.6 ± 22.3 |
| Week 144 | -33.9 ± 20.9 | -36.9 ± 21.3 | -35.9 ± 21.2 |
| Week 168 | -38.0 ± 9.0 | -43.1 ± 20.7 | -41.1 ± 16.5 |
Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.
| percent change | Placebo to Alirocumab 75 or 150 mg Q2W | Alirocumab to Alirocumab 75 or 150 mg Q2W | Alirocumab: All Participants |
|---|---|---|---|
| Week 48 | 5.6 ± 14.5 | 5.8 ± 17.2 | 5.7 ± 16.3 |
| Week 96 | 7.8 ± 15.4 | 8.5 ± 14.1 | 8.3 ± 14.5 |
| Week 144 | 11.2 ± 16.3 | 10.2 ± 18.7 | 10.6 ± 17.8 |
| Week 168 | 0.9 ± 19.3 | 3.9 ± 9.3 | 2.7 ± 13.2 |
Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.
| ratio | Placebo to Alirocumab 75 or 150 mg Q2W | Alirocumab to Alirocumab 75 or 150 mg Q2W | Alirocumab: All Participants |
|---|---|---|---|
| Week 48 | -0.340 ± 0.245 | -0.361 ± 0.304 | -0.354 ± 0.286 |
| Week 96 | -0.340 ± 0.228 | -0.375 ± 0.268 | -0.363 ± 0.256 |
| Week 144 | -0.342 ± 0.242 | -0.414 ± 0.433 | -0.389 ± 0.379 |
| Week 168 | -0.370 ± 0.161 | -0.498 ± 0.280 | -0.447 ± 0.238 |
Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Week 176 post-treatment follow-up visit) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo to Alirocumab 75 or 150 mg Q2W | 4/330 (1.2%) | 68/330 (20.6%) | 183/330 (55.5%) |
| Alirocumab to Alirocumab 75 or 150 mg Q2W | 7/655 (1.1%) | 144/655 (22%) | 366/655 (55.9%) |
| Alirocumab: All Participants | 11/985 (1.1%) | 212/985 (21.5%) | 549/985 (55.7%) |
| Event | Placebo to Alirocumab 75 or 150 mg Q2W | Alirocumab to Alirocumab 75 or 150 mg Q2W | Alirocumab: All Participants |
|---|---|---|---|
| Angina pectorisCardiac disorders | 6/330 | 8/655 | 14/985 |
| Angina unstableCardiac disorders | 4/330 | 5/655 | 9/985 |
| SyncopeNervous system disorders | 1/330 | 6/655 | 7/985 |
| Transient ischaemic attackNervous system disorders | 0/330 | 6/655 | 6/985 |
| Coronary artery stenosisCardiac disorders | 3/330 | 3/655 | 6/985 |
| Cardiac failure congestiveCardiac disorders | 3/330 | 1/655 | 4/985 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 2/330 | 5/655 | 7/985 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 1/330 | 5/655 | 6/985 |
| Acute myocardial infarctionCardiac disorders | 2/330 | 4/655 | 6/985 |
| Coronary artery diseaseCardiac disorders | 2/330 | 4/655 | 6/985 |
| Event | Placebo to Alirocumab 75 or 150 mg Q2W | Alirocumab to Alirocumab 75 or 150 mg Q2W | Alirocumab: All Participants |
|---|---|---|---|
| Viral upper respiratory tract infectionInfections and infestations | 51/330 | 93/655 | 144/985 |
| Upper respiratory tract infectionInfections and infestations | 31/330 | 71/655 | 102/985 |
| InfluenzaInfections and infestations | 34/330 | 61/655 | 95/985 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 34/330 | 53/655 | 87/985 |
| Back painMusculoskeletal and connective tissue disorders | 26/330 | 56/655 | 82/985 |
| Injection site reactionGeneral disorders | 26/330 | 28/655 | 54/985 |
| MyalgiaMusculoskeletal and connective tissue disorders | 15/330 | 44/655 | 59/985 |
| DiarrhoeaGastrointestinal disorders | 19/330 | 43/655 | 62/985 |
| Urinary tract infectionInfections and infestations | 21/330 | 28/655 | 49/985 |
| BronchitisInfections and infestations | 19/330 | 41/655 | 60/985 |
All enrolled participants who received at least one dose or part of a dose of alirocumab in this study. Participant who was not treated, was not included in any analysis.
| Age, Continuous(years) | Placebo to Alirocumab 75 or 150 mg Q2W | Alirocumab to Alirocumab 75 or 150 mg Q2W | Total |
|---|---|---|---|
| Mean | 54.8 ± 11.4 | 54.1 ± 12.1 | 54.4 ± 11.9 |
| Sex: Female, Male(Participants) | Placebo to Alirocumab 75 or 150 mg Q2W | Alirocumab to Alirocumab 75 or 150 mg Q2W | Total |
|---|---|---|---|
| Female | 148 | 287 | 435 |
| Male | 182 | 368 | 550 |
| Ethnicity (NIH/OMB)(Participants) | Placebo to Alirocumab 75 or 150 mg Q2W | Alirocumab to Alirocumab 75 or 150 mg Q2W | Total |
|---|---|---|---|
| Hispanic or Latino | 12 | 27 | 39 |
| Not Hispanic or Latino | 317 | 623 | 940 |
| Unknown or Not Reported | 1 | 5 | 6 |
| Race/Ethnicity, Customized(Participants) | Placebo to Alirocumab 75 or 150 mg Q2W | Alirocumab to Alirocumab 75 or 150 mg Q2W | Total |
|---|---|---|---|
| White | 310 | 628 | 938 |
| Black or African American | 2 | 2 | 4 |
| Asian | 2 | 6 | 8 |
| American Indian or Alaska Native | 1 | 2 | 3 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Other | 4 | 7 | 11 |
| White/Black or African American | 6 | 5 | 11 |
| White/Asian | 2 | 5 | 7 |
| White/American Indian or Alaska Native | 1 | 0 | 1 |
| Black or African American/Asian | 1 | 0 | 1 |
| Calculated LDL-C in mg/dL(mg/dL) | Placebo to Alirocumab 75 or 150 mg Q2W | Alirocumab to Alirocumab 75 or 150 mg Q2W | Total |
|---|---|---|---|
| Mean | 148.8 ± 48.8 | 153.5 ± 55.3 | 152.0 ± 53.2 |
| Calculated LDL-C in mmol/L(mmol/L) | Placebo to Alirocumab 75 or 150 mg Q2W | Alirocumab to Alirocumab 75 or 150 mg Q2W | Total |
|---|---|---|---|
| Mean | 3.854 ± 1.265 | 3.977 ± 1.432 | 3.936 ± 1.379 |
Showing the first 100 of 177 sites across 24 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Dec 2013, a primary completion of Jun 2017 and a completion of Jun 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2018, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alirocumab